The Filing Desk

Beta Bionics vs Butterfly Network

Beta Bionics BBNX · Butterfly Network BFLY · Health Care Equipment

Beta Bionics reported revenue of $100 million in fiscal 2025, about the same as Butterfly Network's $98 million in fiscal 2025. Beta Bionics' revenue grew 53.9% in its latest year, and Butterfly Network's grew 19.0%. Beta Bionics had an operating margin of -71.5%, against -88.5% at Butterfly Network. Free cash flow was −$56 million at Beta Bionics and −$16 million at Butterfly Network.

Side by side

Beta BionicsButterfly Network
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$100M$98M
Revenue growth53.9%19.0%
Revenue growth a year, last 5 years—16.1%
Gross margin55.4%46.9%
Operating margin−71.5%−88.5%
Net margin−73.0%−79.0%
Free cash flow−$56M−$16M
Free cash flow margin−56.1%−16.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count536.7%16.7%
Last close$16.42$6.08
P/E at the last close——
Insider trades, last 12 months—bought $13.1 million, sold $125.5 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Beta BionicsButterfly Network
Operating margin
Percent of revenue
Beta BionicsButterfly Network
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Beta BionicsButterfly Network

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Beta Bionics and Butterfly Network pages.